Results 1 to 10 of about 94,755 (223)

Angiopoietin-like protein 3 (ANGPTL3) deficiency and familial combined hypolipidemia. [PDF]

J Biomed Res, 2019
Three members of the angiopoietin-like (ANGPTL) protein family-ANGPTL3, ANGPTL4 and ANGPTL8- are important regulators of plasma lipoproteins. They inhibit the enzyme lipoprotein lipase, which plays a key role in the intravascular lipolysis of triglycerides present in some lipoprotein classes.
Tarugi P, Bertolini S, Calandra S.
europepmc   +5 more sources

Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance [PDF]

Journal of Lipid Research, 2020
Angiopoietin-like protein (ANGPTL)3 regulates plasma lipids by inhibiting LPL and endothelial lipase (EL). ANGPTL3 inactivation lowers LDL-C independently of the classical LDLR-mediated pathway and represents a promising therapeutic approach for ...
Rene C. Adam, Ivory J. Mintah, Corey A. Alexa-Braun, Lisa M. Shihanian, Joseph S. Lee, Poulabi Banerjee, Sara C. Hamon, Hye In Kim, Jonathan C. Cohen, Helen H. Hobbs, Cristopher Van Hout, Jesper Gromada, Andrew J. Murphy, George D. Yancopoulos, Mark W. Sleeman, Viktoria Gusarova   +15 more
doaj   +2 more sources

Comparison of angiopoietin-like protein 3 and 4 reveals structural and mechanistic similarities. [PDF]

J Biol Chem, 2021
Elevated plasma triglycerides are a risk factor for coronary artery disease, which is the leading cause of death worldwide. Lipoprotein lipase (LPL) reduces triglycerides in the blood by hydrolyzing them from triglyceride-rich lipoproteins to release free fatty acids.
Gunn KH, Gutgsell AR, Xu Y, Johnson CV, Liu J, Neher SB.   +5 more
europepmc   +4 more sources

Serum Angiopoietin-like Protein 3 Level Is Associated with Peripheral Arterial Stiffness in Patients with Coronary Artery Disease [PDF]

Medicina, 2021
Background and Objectives: Angiopoietin-like protein 3 (ANGPTL3) is a secretory protein regulating lipid metabolism. This study evaluated the relationship between serum ANGPTL3 level and peripheral arterial stiffness (PAS) in patients with coronary ...
Chien-Hao Hsiao, Yu-Chih Chen, Ji-Hung Wang, Bang-Gee Hsu   +3 more
doaj   +2 more sources

Genetic inhibition of angiopoietin-like protein-3, lipids, and cardiometabolic risk. [PDF]

Eur Heart J
Abstract Background and Aims RNA-based, antibody-based, and genome editing-based therapies are currently under investigation to determine if the inhibition of angiopoietin-like protein-3 (ANGPTL3) could reduce lipoprotein-lipid levels and atherosclerotic cardiovascular disease (ASCVD) risk.
Gobeil É, Bourgault J, Mitchell PL, Houessou U, Gagnon E, Girard A, Paulin A, Manikpurage HD, Côté V, Couture C, Marceau S, Bossé Y, Thériault S, Mathieu P, Vohl MC, Tchernof A, Arsenault BJ.   +16 more
europepmc   +3 more sources

On the mechanism of angiopoietin-like protein 8 for control of lipoprotein lipase activity

Journal of Lipid Research, 2019
Angiopoietin-like (ANGPTL) 8 is a secreted inhibitor of LPL, a key enzyme in plasma triglyceride metabolism. It was previously reported that ANGPTL8 requires another member of the ANGPTL family, ANGPTL3, to act on LPL.
Oleg Kovrov, Kristian Kølby Kristensen, Erika Larsson, Michael Ploug, Gunilla Olivecrona   +4 more
doaj   +3 more sources

Differential regulation and properties of angiopoietin-like proteins 3 and 4 [PDF]

Journal of Lipid Research, 2005
Angiopoietin-like protein 3 and 4 (Angptl3 and Angptl4) are two members of the angiopoietin-like family of proteins. These two closely related proteins have been reported to similarly affect lipid metabolism through their capacity to inhibit lipoprotein ...
Hongfei Ge, Ji-Young Cha, Harini Gopal, Christopher Harp, Xinxin Yu, Joyce J. Repa, Cai Li   +6 more
doaj   +3 more sources

High-Serum Angiopoietin-Like Protein 3 Levels Associated with Cardiovascular Outcome in Patients with Coronary Artery Disease [PDF]

International Journal of Hypertension, 2020
Background. Angiopoietin-like protein 3 (ANGPTL3) plays a pivotal role in lipid metabolism and angiogenesis, and there is growing interest regarding the association between ANGPTL3 and coronary artery disease (CAD). This study aims to investigate whether
Ming-Chun Chen, Bang-Gee Hsu, Chung-Jen Lee, Ji-Hung Wang   +3 more
doaj   +2 more sources

A novel nanobody-heavy chain antibody against Angiopoietin-like protein 3 reduces plasma lipids and relieves nonalcoholic fatty liver disease [PDF]

Journal of Nanobiotechnology, 2022
Background Nonalcoholic fatty liver disease (NAFLD) is a metabolic disease mainly on account of hypercholesterolemia and may progress to cirrhosis and hepatocellular carcinoma.
Xiaozhi Hu, Jiajun Fan, Qianqian Ma, Lei Han, Zhonglian Cao, Caili Xu, Jingyun Luan, Guangjun Jing, Yanyang Nan, Tao Wu, Yuting Zhang, Hanqi Wang, Yuanzhen Zhang, Dianwen Ju   +13 more
doaj   +2 more sources

Inhibition of Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia. [PDF]

Circulation, 2019
Background: Hypertriglyceridemia is associated with increased cardiovascular risk and may be caused by impaired lipoprotein clearance. Angiopoietin-like protein 3 (ANGPTL3) inhibits lipoprotein lipase activity, increasing triglycerides and other lipids.
Ahmad Z, Banerjee P, Hamon S, Chan KC, Bouzelmat A, Sasiela WJ, Pordy R, Mellis S, Dansky H, Gipe DA, Dunbar RL.   +10 more
europepmc   +3 more sources